The New Eugenics: The Case Against Genetically Modified Humans
By Marcy Darnovsky,
Different Takes (Spring 2000)
| 11. 30. 1999
Published by the Hampshire College Population and Development Program
At the cusp of dot-com frenzy and the biotech century, a group of influential scientists and pundits has begun zealously promoting a new bio-engineered utopia. In the world of their visionary fervor, parents will strive to afford the latest genetic "improvements" for their children. According to the advocates of this human future (or, as some term it, "post-human" future), the exercise of consumer preferences for offspring options will be the prelude to a grand achievement: the technological control of human evolution.
My first close encounter with this techno-eugenic enthusiasm was in a 1997 book written for an unconverted lay audience by Princeton geneticist Lee M. Silver. In Remaking Eden: Cloning and Beyond in a Brave New World (New York: Avon Books 1998), Silver spins out scenarios of a future in which affluent parents are as likely to arrange genetic enhancements for their children as to send them to private school.
Silver confidently predicts that upscale baby-making will soon take place in fertility clinics, where prospective parents will undergo an IVF procedure...
Related Articles
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Sophie Ryall , BioNews | 08.03.2026
A fertility doctor is being sued for using his own sperm during artificial insemination procedures without the patient's knowledge or consent.
Dr Dennis Lutz used his own sperm repeatedly when treating patient Jean Ann Nelson at the Medical Arts Clinic...